person · Reporting owner

Lehrer-Graiwer Joshua

Disclosed activity across 4 companies

Tapewire entity: 50223
SEC CIK: 0001789673

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Fulcrum Therapeutics, Inc.FULC · Entity 5969	Director	April 23, 2026	May 01, 2026
Global Blood Therapeutics, Inc.GBT · Entity 123220	Chief Medical Officer	March 05, 2020	March 09, 2020
LENZ Therapeutics, Inc.GRPH · Entity 6475	Director · PRESIDENT AND CEO	February 21, 2023	February 23, 2023
LISATA THERAPEUTICS, INC.LSTA · Entity 7814	President & COO	September 17, 2026	September 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Fulcrum Therapeutics, Inc.

Report date April 23, 2026 · Filed May 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.08 · Expires 2036-04-22	Direct	64,000	Reported balance After 2026-04-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-23 · Grant · Acquired 64,000 · Balance 64,000 F1: This option was granted on April 23, 2026 and is scheduled to vest in equal monthly installments until April 23, 2029, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on April 23, 2026 and is scheduled to vest in equal monthly installments until April 23, 2029, subject to continued service.

Global Blood Therapeutics, Inc.

Report date March 05, 2020 · Filed March 09, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,595	Ending reported balance After 2020-03-09 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2020-03-05 · Sale · Disposed 1,138 · Balance 2,595 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Row 2 · 2020-03-09 · Exercise / conversion · Acquired 938 · Balance 3,533 Row 3 · 2020-03-09 · Sale · Disposed 938 · Balance 2,595 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: Represents the weighted average sale price of the shares sold ranging from $59.80 to $60.00 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.89 · Expires 2026-09-07	Direct	1,875	Reported balance After 2020-03-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-03-09 · Exercise / conversion · Disposed 938 · Balance 1,875 F3: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: Represents the weighted average sale price of the shares sold ranging from $59.80 to $60.00 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

LENZ Therapeutics, Inc.

Report date February 21, 2023 · Filed February 23, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2033-02-20	Direct	600,000	Reported balance After 2023-02-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-02-21 · Grant · Acquired 600,000 · Balance 600,000 F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.

LISATA THERAPEUTICS, INC.

Report date September 17, 2026 · Filed September 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	21,548	Reported balance Holding disclosure · report date 2026-09-17 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 21,548 F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 3,400,043 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis) (the "Preferred Share Exchange Ratio"). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible F2: (continued from Footnote 1) Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.
Common StockSEC Table I · non-derivative	IndirectSee footnote	6,260	Reported balance Holding disclosure · report date 2026-09-17 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 6,260 F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 3,400,043 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis) (the "Preferred Share Exchange Ratio"). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible F2: (continued from Footnote 1) Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements. F3: The shares are held by the Lehrer Family Irrevocable GST Exempt Trust U/A/D November 21, 2025.
Series C Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-17 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 3,400,043 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis) (the "Preferred Share Exchange Ratio"). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible F2: (continued from Footnote 1) Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.
Series C Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	Not disclosed	Reported balance Holding disclosure · report date 2026-09-17 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 3,400,043 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis) (the "Preferred Share Exchange Ratio"). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible F2: (continued from Footnote 1) Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements. F3: The shares are held by the Lehrer Family Irrevocable GST Exempt Trust U/A/D November 21, 2025.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $318.85 · Expires 2034-10-28	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-17 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $318.85 · Expires 2034-10-28	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-17 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $709.69 · Expires 2036-03-31	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-17 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance Not disclosed F6: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $5.01 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the closing price on first listing, or the trailing average described above. F7: (continued from Footnote 6) The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement. F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $709.69 · Expires 2036-03-31	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-17 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance Not disclosed F8: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $8.35 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the F9: (continued from Footnote 8) closing price on first listing, or the trailing average described above. The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement. F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $545.13 · Expires 2036-03-31	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-17 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance Not disclosed F6: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $5.01 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the closing price on first listing, or the trailing average described above. F7: (continued from Footnote 6) The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement. F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $545.13 · Expires 2036-03-31	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-17 · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · Balance Not disclosed F8: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $8.35 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the F9: (continued from Footnote 8) closing price on first listing, or the trailing average described above. The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement. F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4.

Filing footnotes · ownership attribution and instrument terms

F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 3,400,043 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis) (the "Preferred Share Exchange Ratio"). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible

F2: (continued from Footnote 1) Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.

F3: The shares are held by the Lehrer Family Irrevocable GST Exempt Trust U/A/D November 21, 2025.

F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date.

F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4.

F6: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $5.01 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the closing price on first listing, or the trailing average described above.

F7: (continued from Footnote 6) The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement.

F8: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $8.35 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the

F9: (continued from Footnote 8) closing price on first listing, or the trailing average described above. The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 26, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	11,593	$59.60	$690,942.80	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 15 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	656	$0.00 Strike: $26.90	$0.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · derivative · entry 23 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,563 Underlying: Common Stock · 656 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from February 17, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	4,594	$0.00 Strike: $26.90	$0.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · derivative · entry 22 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,219 Underlying: Common Stock · 4,594 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from February 17, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	298	$0.00 Strike: $19.89	$0.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · derivative · entry 21 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 298 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	447	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · derivative · entry 20 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 447 shares Expires 2025-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares of Common Stock underlying this option are fully vested. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	3,515	$0.00 Strike: $27.90	$0.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · derivative · entry 19 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,469 Underlying: Common Stock · 3,515 shares Expires 2027-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from July 26, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	1,108	$0.00 Strike: $19.89	$0.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · derivative · entry 18 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,048 Underlying: Common Stock · 1,108 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	312	$0.00 Strike: $12.95	$0.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · derivative · entry 17 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 Underlying: Common Stock · 312 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from February 9, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	656	$60.00	$39,360.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 14 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	656	$26.90	$17,646.40	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 13 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	4,594	$60.00	$275,640.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 12 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	4,594	$26.90	$123,578.60	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 11 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	298	$60.00	$17,880.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 10 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	298	$19.89	$5,927.22	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 9 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	447	$60.00	$26,820.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 8 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	447	$20.00	$8,940.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 7 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	3,515	$60.00	$210,900.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 6 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	3,515	$27.90	$98,068.50	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 5 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,108	$60.00	$66,480.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 4 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	1,108	$19.89	$22,038.12	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	312	$60.00	$18,720.00	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document
November 25, 2019 Filed Nov 27, 2019 16:47 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	312	$12.95	$4,040.40	Disclosure SEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 19, 2019 Filed Nov 20, 2019 18:11 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	6,562	$0.00 Strike: $48.44	$0.00	Disclosure SEC source: 0000899243-19-027721 · doc4.xml · derivative · entry 6 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,438 Underlying: Common Stock · 6,562 shares Expires 2029-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 19, 2019 Filed Nov 20, 2019 18:11 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	6,562	$55.00	$360,910.00	Disclosure SEC source: 0000899243-19-027721 · doc4.xml · nonDerivative · entry 4 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document
November 19, 2019 Filed Nov 20, 2019 18:11 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	6,562	$48.44	$317,863.28	Disclosure SEC source: 0000899243-19-027721 · doc4.xml · nonDerivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 18, 2019 Filed Nov 20, 2019 18:11 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	656	$0.00 Strike: $26.90	$0.00	Disclosure SEC source: 0000899243-19-027721 · doc4.xml · derivative · entry 5 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,813 Underlying: Common Stock · 656 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from February 17, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 18, 2019 Filed Nov 20, 2019 18:11 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	656	$50.63	$33,213.28	Disclosure SEC source: 0000899243-19-027721 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document
November 18, 2019 Filed Nov 20, 2019 18:11 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	656	$26.90	$17,646.40	Disclosure SEC source: 0000899243-19-027721 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	4,594	$0.00 Strike: $26.90	$0.00	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · derivative · entry 16 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,469 Underlying: Common Stock · 4,594 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from February 17, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	298	$0.00 Strike: $19.89	$0.00	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · derivative · entry 15 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,156 Underlying: Common Stock · 298 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares of Common Stock underlying this option vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	118	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · derivative · entry 14 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447 Underlying: Common Stock · 118 shares Expires 2025-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares of Common Stock underlying this option are fully vested. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	3,516	$0.00 Strike: $27.90	$0.00	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · derivative · entry 13 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,984 Underlying: Common Stock · 3,516 shares Expires 2027-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from July 26, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	1,109	$0.00 Strike: $19.89	$0.00	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · derivative · entry 12 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,454 Underlying: Common Stock · 1,109 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares of Common Stock underlying this option vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	313	$0.00 Strike: $12.95	$0.00	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · derivative · entry 11 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 937 Underlying: Common Stock · 313 shares Expires 2025-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares of Common Stock underlying this option are fully vested. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	9,948	$50.00	$497,446.76	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · nonDerivative · entry 9 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.02 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	4,594	$26.90	$123,578.60	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · nonDerivative · entry 8 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	298	$19.89	$5,927.22	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · nonDerivative · entry 7 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	118	$20.00	$2,360.00	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · nonDerivative · entry 6 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	3,516	$27.90	$98,096.40	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · nonDerivative · entry 5 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	1,109	$19.89	$22,058.01	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · nonDerivative · entry 4 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	313	$12.95	$4,053.35	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · nonDerivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 14, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	329	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · derivative · entry 10 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565 Underlying: Common Stock · 329 shares Expires 2025-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares of Common Stock underlying this option are fully vested. Read SEC document
November 14, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	329	$50.01	$16,454.51	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.045 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 14, 2019 Filed Nov 18, 2019 17:43 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	329	$20.00	$6,580.00	Disclosure SEC source: 0000899243-19-027545 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 01, 2019 Filed Oct 3, 2019 19:19 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	1,500	$0.00	$0.00	Disclosure SEC source: 0000899243-19-024981 · doc4.xml · derivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The shares of Common Stock underlying the RSUs shall vest in 8 equal semi-annual installments over 4 years from October 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The shares of Common Stock underlying the RSUs shall vest in 8 equal semi-annual installments over 4 years from October 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
October 01, 2019 Filed Oct 3, 2019 19:19 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $46.99	$0.00	Disclosure SEC source: 0000899243-19-024981 · doc4.xml · derivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-09-30 F1 · derivative.exercise_date: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from October 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.